They highlight the importance of individualized care, the potential need for adjustments in treatment plans, and the value of patient education and support networks
Lillys Retatrutide: Toward the End of Incremental Metabolic Medicine Why GLP-1++ therapies are redefining what is worth developing and what is not In early December 2025, Eli Lilly announced landmark Phase 3 results for retatrutide its investigational once-weekly triple hormone receptor agonist targeting GLP-1, GIP, and glucagon
While BPC-157 is a gut health powerhouse, its usefulness doesnt stop there
This article examines the evidence, mechanisms, and practical management strategies for headaches associated with weight loss injections
1), fluorescence was measured by flow cytometry (ex 488 nm/em 520 nm) (FACSCanto II, BD)